Subscribe

The best and worst performers among sector funds: Health Care and Biotechnology

The best and worst performers among sector funds: Health Care and Biotechnology Click column headers to…

The best and worst performers among sector funds: Health Care and Biotechnology

Click column headers to sort fields



3 months 1 year 3 years 3-year std dev Expense ratio
TOP 10          
Touchstone Health & Biotech A 9.18 25.49 14.56 9.58 1.85
iShares DJ U.S. Healthcare Providers Index 6.59 21.83 n/a n/a 0.48
BlackRock Healthcare A 7.65 20.86 13.87 10.08 1.57
Janus Global Life Sciences 9.49 20.54 13.1 9.51 1.02
BlackRock Health Sciences Ops Inv A 10.21 20.54 18.23 10.18 1.34
iShares DJ U.S. Medical Devices Index 3.54 20.48 n/a n/a 0.48
SPDR S&P Biotech 9.11 20.42 n/a n/a 0.35
T. Rowe Price Health Sciences 7.29 19.91 16.39 10.42 0.87
Fidelity Select Medical Delivery 6.99 19.44 16.22 9.84 0.95
PowerShares Dynamic Health Care Svcs 4.9 17.45 n/a n/a 0.7
           
BOTTOM 5          
Franklin Biotechnology Discovery 3.16 4.21 7.23 16.4 1.35
John Hancock Health Sciences A 5.23 4.29 8.97 9.94 1.52
Putnam Health Sciences A 3.09 4.46 8.95 8.18 1.17
PowerShares Dynamic Pharmaceuticals 4.03 4.6 n/a n/a 0.63
iShares Nasdaq Biotechnology 6.36 5.04 6.1 15.09 0.48
Lipper category average 6.12 12.65 11.98 9.63 1.382
Unfiltered Lipper category average 5.42 11.73 10.52 10.36 1.64

Related Topics:

Learn more about reprints and licensing for this article.

Recent Articles by Author

Follow the data to ID the best prospects

Advisers play an important role in grooming the next generation of savvy consumers, which can be a win-win for clients and advisers alike.

Advisers need to get real with clients about what reasonable investment returns look like

There's a big disconnect between investor expectations and stark economic realities, especially among American millennials.

Help clients give wisely

Not all charities are created equal, and advisers shouldn't relinquish their role as stewards of their clients' wealth by avoiding philanthropy discussions

Finra, it’s high time for transparency

A call for new Finra leadership to be more forthcoming about the board's work.

ETF liquidity a growing point of financial industry contention

Little to indicate the ETF industry is fully prepared for a major rush to the exits by investors.

X

Subscribe and Save 60%

Premium Access
Print + Digital

Learn more
Subscribe to Print